MNC pharma: Time to re-look at them without bias? 8 MNC pharma stocks, 5 with an upside potential of 15 to 52%

While they still trade at premium valuations, they have not created much wealth for shareholders in recent times. The age-old theory that having MNC stocks in your portfolio is an assurance of growth and returns no longer holds true. Once upon a time, owning MNC stocks, irrespective of the sector, was important as they were liberal with bonuses and dividends. Also, some of them owned the best brands which delivered secular growth, allowing them to be generous to shareholders. But maybe it is time to shed the bias against them, especially MNC pharma firms which have gone through restructuring.